Navigation Links
NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
Date:11/30/2009

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

This study enrolled 467 older adults in a three-arm study at six different sites located within the United States. In addition to evaluating hemagglutinin inhibition (HAI) responses, anti-neuraminidase and cell-mediated immune responses are also being examined. Previous studies have shown that VLP-based flu vaccines drive strong neuraminidase inhibition (NAI) antibody titers and T-cell responses, indicating the potential for broader immunologic responses particularly in older adults.

"With the rapid completion of enrollment in this clinical trial as well as the first part of our H1N1 vaccine study in Mexico announced previously, we are on track to report results from our two most advanced clinical programs during the first quarter of next year," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "If results from the seasonal flu vaccine study are positive, we will be able to advance this program into Phase III clinical testing as early as 2010."

Seasonal Influenza

Seasonal influenza infects between 5 percent and 20 percent of the world's population and kills between 250,000 and 500,000 people each year. In the United States, the Centers for Disease Control and Prevention estimates th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Prices Public Offering of Common Stock
2. NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
3. Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
4. NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
5. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
6. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
7. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
8. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
9. Novavax Announces Board of Director Changes
10. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
11. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Efficient Cellular Fractionation for RNA , ... Ambion's Protein and RNA Isolation System, , ... total RNA and native protein from the same ... tissues that are either fresh, , ...
... Because of its apparent specificity, , ... accelerating the functional characterization of , ... and basic research efforts. To ensure ... data, however, proper experimental design and controls are , ...
... mir ... Sensitive -- Detect miRNA or siRNA in as little as 10 ng ... need to optimize hybridization , or washing conditions , ... to membrane for hybridization , ...
Cached Biology Technology:Efficient Cellular Fractionation for RNA , and Protein Isolation 2Efficient Cellular Fractionation for RNA , and Protein Isolation 3Efficient Cellular Fractionation for RNA , and Protein Isolation 4Efficient Cellular Fractionation for RNA , and Protein Isolation 5Efficient Cellular Fractionation for RNA , and Protein Isolation 6Efficient Cellular Fractionation for RNA , and Protein Isolation 7Designing Controls for siRNA , Experiments 2Designing Controls for siRNA , Experiments 3Designing Controls for siRNA , Experiments 4Designing Controls for siRNA , Experiments 5Detecting Attomole Amounts of Small RNA 2Detecting Attomole Amounts of Small RNA 3
(Date:4/17/2014)... 16, 2014. Kessler Foundation has been named awardee ... the Department of Defense Spinal Cord Injury Research ... for the randomized, double-blinded, controlled, multi-site clinical trial, ... muscle strength after spinal cord injury. Dr. Forrest ... Research at Kessler Foundation. Two additional sites will ...
(Date:4/17/2014)... This news release is available in German . ... enable us to recognise objects; they also provide us with ... we run, turn around, fall or sit still in a ... characteristic motion trace on our retinas. Seemingly without effort, our ... can maintain a stable position and a steady gaze during ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... RICHMOND, Va. (April 19, 2010) Virginia Commonwealth University ... play a key role in the development of liver ... in more than 90 percent of patients with the ... at the Virginia Commonwealth University Massey Cancer Center and ...
... Chesapeake Biological Laboratory Director Dr. Margaret Palmer has been ... Science with its President,s Award for Excellence in Science ... about the environmental impacts of mountaintop mining. "Day ... the impact of her research beyond academia and into ...
... hard metals or semiconductors to soft organic or biological products. ... by Mother Nature. The applications in medicine and ... face of nanoscience at The Florida State University. ... a chip" that can diagnose illness? That and much more ...
Cached Biology News:Researchers identify new gene involved in the development of liver cancer 2UMCES ecologist Margaret Palmer recognized for promoting the role of science in public policy 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: